CBAY Cymabay Therapeutics

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Company profile

Sujal Shah
Fiscal year end
Former names

CBAY stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


25 Mar 21
13 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 28.19M 28.19M 28.19M 28.19M 28.19M 28.19M
Cash burn (monthly) 6.36M (positive/no burn) 5.29M 4.38M 4.94M 3.73M
Cash used (since last report) 21.9M n/a 18.22M 15.09M 17M 12.83M
Cash remaining 6.3M n/a 9.98M 13.1M 11.19M 15.36M
Runway (months of cash) 1.0 n/a 1.9 3.0 2.3 4.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Apr 21 Wiggans Thomas G Stock Option Common Stock Grant Aquire A No No 4.63 80,000 370.4K 80,000
5 Apr 21 Janet Dorling Stock Option Common Stock Grant Aquire A No No 4.63 80,000 370.4K 80,000
26 Jan 21 Paul T Quinlan Employee Stock Option Common Stock Grant Aquire A No No 5.78 22,167 128.13K 22,167

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

86.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 147 120 +22.5%
Opened positions 47 29 +62.1%
Closed positions 20 24 -16.7%
Increased positions 41 28 +46.4%
Reduced positions 36 42 -14.3%
13F shares
Current Prev Q Change
Total value 2.8B 3.07B -8.7%
Total shares 59.41M 58.05M +2.3%
Total puts 661.4K 131.3K +403.7%
Total calls 307.3K 450.2K -31.7%
Total put/call ratio 2.2 0.3 +638.0%
Largest owners
Shares Value Change
Avoro Capital Advisors 10.3M $59.12M 0.0%
BLK Blackrock 5.39M $30.92M +5.0%
Boxer Capital 4M $22.96M 0.0%
Vanguard 3.43M $19.67M +1.6%
Baker Bros. Advisors 2.89M $16.61M -11.0%
Citadel Advisors 2.52M $14.48M +13.6%
STT State Street 1.81M $10.38M +10.2%
Foresite Capital Fund III 1.79M $10.26M NEW
Foresite Capital Management IV 1.79M $10.26M 0.0%
Foresite Capital Management III 1.64M $9.42M 0.0%
Largest transactions
Shares Bought/sold Change
Foresite Capital Fund III 1.79M +1.79M NEW
Redmile 0 -1.72M EXIT
IVZ Invesco 216.41K -1.66M -88.5%
Vivo Capital 585.39K -1.5M -72.0%
Commodore Capital 1.49M +1.49M NEW
D. E. Shaw & Co 1.26M +1.26M NEW
Two Sigma Investments 1.12M +870.58K +355.5%
GS Goldman Sachs 940.98K +850.4K +938.9%
Two Sigma Advisers 1.22M +807.3K +197.8%
Voya Investment Management 245.22K -600.28K -71.0%
Content analysis
H.S. freshman Avg
New words: Abbvie, accidental, acquireor, adapted, adapting, AdventHealth, Aid, Air, alter, analogue, anesthesiologist, answer, ascending, Assembly, ASUNo, attenuate, Bay, behavior, Biden, blended, bythe, CAA, Cadila, Canada, cap, carryback, carryover, Charitable, climate, closure, complaint, complimentary, confidence, constitutionality, contamination, coronavirusdisease, degradation, Delinquent, diary, distancing, drafting, economy, efficiently, energy, ente, exhaustive, expert, factor, Fast, FFCR, float, Florida, forfeited, forgiven, franchise, Francisco, fromour, gas, globe, goodwill, greenhouse, Harry, Helmsley, home, hypoglycemia, innate, internationally, intraperiod, Language, Leona, lowest, Madrigal, marketplace, methodology, misuse, Nation, national, nationwide, Nordisk, Northern, Novo, nurse, ofthe, onForm, opportunistically, opposition, Orlando, outbreak, pandemic, patientswith, payer, pleadingsthat, precautionary, proactive, prorated, published, quarantine, reconsider, red, redit, reexamining, refundable, reinstate, reinstatement, remote, remotely, Resmitiron, San, saroglitizar, securitiesand, semaglutide, sequester, shut, shutdown, social, spread, spreadof, SRC, sugar, supranational, Supreme, thatthe, thedisease, theongoing, THRb, tie, titration, Topline, Trust, Tvardi, unanimously, unnecessary, unspecified, uoted, view, vigorously, waive, Whilethe, workplace
Removed: adjustment, Allergan, Alto, AP, Arena, assessment, ASU, attestation, Berkeley, Biochemistry, closing, commitment, conform, crystal, denominator, division, earned, Enanta, etrasimod, expired, Gilead, governance, grow, incretin, indexed, instrument, Kowa, lender, Likewise, lipoprotein, loan, lowering, maralixibat, Martin, MBA, modulator, negotiating, nonemployee, OCA, opted, outlined, Palo, Patrick, Ph, placement, Pol, practical, preclude, protected, receivable, reclassified, refinanced, reliable, remeasured, remeasurement, renal, resource, revaluation, revalued, Roche, SA, selonsertib, settlement, show, Sr, sulfate, Tepper, terminating, transition, tropifexor, unvested, upfront, uric, variant, warrant